PKBO Stock Overview
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Peak Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0085 |
| 52 Week High | US$1.00 |
| 52 Week Low | US$0.002 |
| Beta | 0.53 |
| 1 Month Change | 66.67% |
| 3 Month Change | -77.45% |
| 1 Year Change | -98.79% |
| 3 Year Change | -99.91% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 63.5% | 0.1% | 2.2% |
| 1Y | -98.8% | -1.0% | 22.8% |
Return vs Industry: PKBO underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: PKBO underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| PKBO volatility | |
|---|---|
| PKBO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PKBO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PKBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 21 | Steve LaMond | peak-bio.com |
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company’s lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors.
Peak Bio, Inc. Fundamentals Summary
| PKBO fundamental statistics | |
|---|---|
| Market cap | US$192.38k |
| Earnings (TTM) | -US$21.18m |
| Revenue (TTM) | US$467.67k |
0.4x
P/S Ratio0.0x
P/E RatioIs PKBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKBO income statement (TTM) | |
|---|---|
| Revenue | US$467.67k |
| Cost of Revenue | US$2.43m |
| Gross Profit | -US$1.97m |
| Other Expenses | US$19.21m |
| Earnings | -US$21.18m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -420.41% |
| Net Profit Margin | -4,528.09% |
| Debt/Equity Ratio | -23.1% |
How did PKBO perform over the long term?
See historical performance and comparison